The EHMT1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human hepatic adenocarcinoma line SK-HEP-1. This loss-of-function model targets EHMT1 (GLP), a key histone methyltransferase, via CRISPR/Cas9-mediated gene disruption without single-cell cloning. The resulting heterogeneous cell pool carries diverse EHMT1-disrupted alleles, capturing a spectrum of knockout effects for functional studies under near-physiological conditions.
The SK-HEP-1 host cell line originated from the ascites of a liver adenocarcinoma patient and exhibits both mesenchymal and epithelial characteristics. This mixed phenotype makes it particularly useful for investigating epithelial?mesenchymal transition (EMT) and metastatic behavior in hepatocellular carcinoma. The line is well?characterized and widely employed in liver cancer biology, hepatocyte signaling, and drug metabolism research.
EHMT1 catalyzes mono- and dimethylation of histone H3 at lysine 9 (H3K9me1/me2), creating repressive marks bound by HP1 proteins (e.g., HP1??) to drive transcriptional silencing and heterochromatin formation. It functions as a heterodimer with EHMT2 (G9a) and is recruited to chromatin by transcription factors REST and E2F6. EHMT1 interacts with UHRF1, NuRD complex components (CHD4), and HP1 proteins to establish stable repression. Downstream targets include BDNF, SYN1, CDKN1A, CDH1, and VIM, while its activity is modulated by WNT signaling components. Thus, EHMT1 links extracellular signals to the epigenome.
In SK-HEP-1 liver cancer cells, EHMT1-mediated H3K9 methylation likely silences genes restraining proliferation and migration. Knockout is expected to derepress these targets, potentially reactivating cell cycle inhibitors, altering EMT marker expression, and attenuating Wnt?driven programs. This model enables dissection of EHMT1??s role in hepatocellular carcinoma progression and metastasis, and provides a platform to study cross?talk between chromatin modification and oncogenic pathways.
Applications include mechanistic studies of epigenetic gene silencing, validation of EHMT1 inhibitors, investigation of EMT and metastasis, and modeling of neurodevelopmental disorders linked to EHMT1. Representative assays encompass western blotting for EHMT1 and H3K9me1/me2, RT?qPCR of target genes (BDNF, CDKN1A), ChIP?qPCR for H3K9me2 at promoters, immunofluorescence for H3K9me distribution, and migration/invasion and proliferation assays. Transcriptome?wide effects can be evaluated by RNA?seq. For further details, please contact Ascent Research.
